SOURCE: PharmaRoth Labs, Inc.

May 03, 2016 08:30 ET

PharmaRoth Labs Announces Integration of HSBC Credit Facilities

LAS VEGAS, NV--(Marketwired - May 3, 2016) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, today announced that it has successfully closed on the integration of its "Automatic Invoice Discounting" credit facilities with HSBC Mexico S.A. ("HSBC"). The credit facilities allow the company to receive payment through HSBC, derived from both new and existing purchase orders.

"Integrating the management of our credit facility with HSBC in Mexico will allow us to more easily finance our working capital needs as the demand for our product in Mexico continues to improve," commented Luis Lopez, CEO of PharmaRoth.

Mr. Lopez further states: "Having a global financial leader like HSBC as our banking partner in Mexico is clearly an important milestone for the company. With HSBC we can handle any size and frequency of orders which also strengthens our relationship with our distributor MDR," Mr. Lopez concluded. 

About Sucanon®

Sucanon® is a diabetes oral treatment containing natural ingredients. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, and Canada and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit www.pharmaroth.com

About PharmaRoth

PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For Investor Relations contact:

    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462
    mike@parvise.com